Department of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medical, Nanjing 210002, China.
Transl Lung Cancer Res. 2015 Apr;4(2):203-8. doi: 10.3978/j.issn.2218-6751.2015.03.02.
Observational studies on the prognostic role of programmed cell death-ligand 1 (PD-L1) in non-small cell lung cancer (NSCLC) are controversial.
To clarify the impact of PD-L1 in NSCLC survival, we performed this meta-analysis that included eligible studies. The combined hazard ratios (HR) and their corresponding 95% confidence intervals (CIs) were calculated in terms of overall survival.
A total of five studies with 877 patients were evaluable for this meta-analysis. Our results suggested that PD-L1 overexpression had a poor impact on survival of patients with NSCLC, the HR (95% CI) was 1.43 (1.24-1.63) overall, 1.51 (1.24-1.7954) in Asian patients, 1.35 (1.08-1.63) in non-Asian patients. Moreover, there was no heterogeneity between the studies.
PD-L1 overexpression indicates a poor prognosis for patients with NSCLC.
关于程序性死亡配体 1（PD-L1）在非小细胞肺癌（NSCLC）中的预后作用的观察性研究结果存在争议。
为了阐明 PD-L1 在 NSCLC 生存中的影响，我们进行了这项荟萃分析，其中包括符合条件的研究。根据总生存率计算合并风险比（HR）及其相应的 95%置信区间（CI）。
共有五项研究，共 877 名患者可用于本荟萃分析。我们的结果表明，PD-L1 过表达对 NSCLC 患者的生存有不良影响，HR（95%CI）总体为 1.43（1.24-1.63），亚洲患者为 1.51（1.24-1.7954），非亚洲患者为 1.35（1.08-1.63）。此外，研究之间没有异质性。
PD-L1 过表达表明 NSCLC 患者预后不良。
